{"id":12405,"date":"2011-10-07T15:57:38","date_gmt":"2011-10-07T19:57:38","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=12405"},"modified":"2011-10-07T15:57:38","modified_gmt":"2011-10-07T19:57:38","slug":"fda-approves-juvisync-combination-of-sitagliptin-and-simvastatin","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/10\/07\/fda-approves-juvisync-combination-of-sitagliptin-and-simvastatin\/","title":{"rendered":"FDA Approves Juvisync, Combination of Sitagliptin and Simvastatin"},"content":{"rendered":"<p>The FDA has approved a fixed-dose combination tablet consisting of sitagliptin and simvastatin, two drugs previously approved for type 2 diabetes and hypercholesterolemia. Merck will market the new drug as Juvisync.<\/p>\n<p>\u201cThis is the first product to combine a type 2 diabetes drug with a cholesterol lowering drug in one tablet,\u201d said Mary H. Parks, the director of the Division of Metabolism and Endocrinology Products in the FDA&#8217;s Center for Drug Evaluation and Research, in\u00a0<a href=\"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm274748.htm\">an FDA press release<\/a>. \u201cHowever, to ensure safe and effective use of this product, tablets containing different doses of sitagliptin and simvastatin in fixed-dose combination have been developed to meet the different needs of individual patients.\u00a0Dose selection should factor in what other drugs the patient is taking.\u201d<\/p>\n<p>The FDA said it had approved dosage strengths for sitagliptin\/simvastatin of 100 mg\/10 mg, 100 mg\/20 mg, and 100 mg\/40 mg. Other dosage combinations are under development.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has approved a fixed-dose combination tablet consisting of sitagliptin and simvastatin, two drugs previously approved for type 2 diabetes and hypercholesterolemia. Merck will market the new drug as Juvisync. \u201cThis is the first product to combine a type 2 diabetes drug with a cholesterol lowering drug in one tablet,\u201d said Mary H. Parks, [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7],"tags":[662,534,1011],"class_list":["post-12405","post","type-post","status-publish","format-standard","hentry","category-general","category-prevention","tag-combination-therapy","tag-simvastatin","tag-sitagliptin"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/12405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=12405"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/12405\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=12405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=12405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=12405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}